article thumbnail

Atlas Venture 2024 Year In Review

LifeSciVC

Ironically, this is how biotech feels right now in November 2024, dealing with the shockwaves of Trump’s nomination of RFK Jr as the nation’s new health czar. In the past few weeks, we’ve held our 2024 Annual General Meeting for our Limited Partners (our investors) and our Atlas Venture Retreat with industry executives.

article thumbnail

Fossil fuel CO2 emissions increase again in 2024

Science Daily: Pharmacology News

Global carbon emissions from fossil fuels have reached a record high in 2024, according to new research.

Research 114
article thumbnail

Keypoint Newsletter: September 2024

keypoint

Checkout Health Equity highlights, climate & sustainability conferences, emerging topics & more from Keystone Symposia in our September 2024 Keypoint Newsletter.

88
article thumbnail

Lab Innovations 2024 to champion sustainability and innovation

Drug Discovery Today

London, 25/04/2024: The lab industry’s largest annual trade show is returning to the NEC, Birmingham, on October 30 and 31, 2024, to showcase sustainability and the latest innovations from the lab industry.

113
113
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

📆 November 21, 2024 at 11:00 AM PST, 2:00 PM EST, 7:00 PM GMT

article thumbnail

Keypoint Newsletter: 2024 Season Highlights

keypoint

In June we wrapped up our 2024 conference season, aligning with the academic calendar. Altogether we hosted 52 conferences across North America, Europe and Asia, serving nearly 9,000 participants and providing financial aid to over 500 students, post-docs, underrepresented scientists and scientists from low- and middle-income countries.

Science 83
article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

Tirzepatide is also trialing in a Phase 3 obese HFpEF trial, and top-line readout in 2H 2024 will suggest whether the increased weight loss achieved with dual GLP1/GIPR modulation further improves QoL and functional endpoints. ALT) continue to build momentum in the indication. Will incretins “solve” MASH in obese patients?